Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg upgrades ITM Power to 'buy', raises target price

(Sharecast News) - Analysts at Berenberg upgraded PEM electrolysers manufacturer ITM Power from 'hold' to 'buy' on Monday, noting that the group appears to be "approaching its inflection point". Berenberg said that over the last two years, ITM had streamlined the business and its product offering, and transformed its manufacturing capabilities.

As previous legacy contracts are delivered, and the company ramps up production, Berenberg said it begins to see "a glide path to profitability".

"As these orders are delivered, our focus will turn to the potential orders from the recent series of announcements that signal over 500MW of orders and £350m-450m of potential revenue, 3x bigger than the current order book," said Berenberg.

The German bank, which hiked its target price on the stock from 59p to 100p, said it believes that ITM can scale up and deliver a roughly 20% gross margin on these orders, driving a "significant increase in the profitability of the business". It also noted that this potential backlog does not include the expected ramp-up in orders and delivery of NEPTUNE V contracts in the coming years.

"We amend our longer-term forecasts in line with our view that the company will build on its inflection point in FY28 and increase profitability thereafter. We now focus on a DCF and multiple-based approach to valuation. Given the significant and growing market backdrop for green hydrogen in ITM's target markets and improved operational delivery, and as we approach the inflection point, we upgrade to 'buy'," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.